Atria Investments Inc Has $2.55 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Atria Investments Inc increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,517 shares of the life sciences company’s stock after purchasing an additional 364 shares during the quarter. Atria Investments Inc’s holdings in Illumina were worth $2,545,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in shares of Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after buying an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new position in Illumina during the second quarter worth about $34,000. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $61,000. Finally, Mizuho Securities Co. Ltd. bought a new stake in shares of Illumina during the 2nd quarter valued at approximately $63,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on ILMN. Scotiabank dropped their price objective on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research note on Thursday, August 15th. TD Cowen increased their price target on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Daiwa America upgraded Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Canaccord Genuity Group increased their target price on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. Finally, Hsbc Global Res raised Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $164.00.

Illumina Trading Down 2.7 %

NASDAQ ILMN opened at $142.24 on Friday. The stock has a market capitalization of $22.56 billion, a P/E ratio of -14.68 and a beta of 1.13. The business has a 50 day simple moving average of $139.20 and a 200 day simple moving average of $124.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a one year low of $92.69 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter last year, the firm posted $0.33 EPS. The company’s quarterly revenue was down 3.5% on a year-over-year basis. Research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.